Live Breaking News & Updates on Consolidated Operating Expenses

Stay updated with breaking news from Consolidated operating expenses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ionis reports fourth quarter and full year 2023 financial results

WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year
Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE,. ....

Elizabethl Hougen , Company Phase , Ionis Pharmaceuticals , Foundation For Angelman Syndrome Therapeutics Summit , Akcea Therapeutics Inc , Ionis Pharmaceuticals Inc , Exchange Commission , Technology Advancement , Breakthough Therapy , Full Year , Fast Track , Breakthrough Therapy , Angelman Syndrome Therapeutics , Royalty Pharma , Serum Vitamin , Recommended Supplementation , Prescribing Information , Akcea Therapeutics , Consolidated Statements , Except Per Share Data , Consolidated Operating Expenses , From Operations , Net Income , Selected Financial Information , Data Events ,

Ionis reports fourth quarter and full year 2022 financial results

/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), a genetic medicines company, today reported financial results for the fourth. ....

Ionis Pharmaceuticals Inc , Advisory Committee , Exchange Commission , Prnewswire Ionis Pharmaceuticals Inc , Technology Advancement , Ionis Pharmaceuticals , Akcea Therapeutics Inc , Fast Track , Full Year , Related Tax , Royalty Pharma , Akcea Therapeutics , Consolidated Statements , Except Per Share Data , Consolidated Operating Expenses , From Operations , Net Income , North American , Selected Financial Information , Financial Impacts , Eplontersen Collaboration , Year Ended , Ioni Statement , Total Phase , Ioni Phase , Value Driving ,

Ionis reports third quarter financial results

/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2022. Financial results. ....

Ionis Pharmaceuticals Inc , Exchange Commission , Prnewswire Ionis Pharmaceuticals Inc , Ionis Pharmaceuticals , Akcea Therapeutics Inc , Technology Advancements , Drug Application , Prescription Drug User Fee Act , Akcea Therapeutics , Consolidated Statements , Except Per Share Data , Consolidated Operating Expenses , Loss From Operations , North American , Selected Financial Information , Financial Impacts , Eplontersen Collaboration , Nine Months Ended , Ioni Statement , Total Phase , Ioni Phase ,

Ionis reports second quarter financial results and recent business achievements

/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the second quarter of 2022 and recent business achievements.. ....

United States , Elizabethl Hougen , Ionis Pharmaceuticals Inc , Drug Administration , Exchange Commission , European Network To Cure , Prnewswire Ionis Pharmaceuticals Inc , Ionis Pharmaceuticals , Akcea Therapeutics Inc , Technology Advancements , International Liver Congress , International Symposium , Financial Results , Latin America , Swedish Orphan Biovitrum , Recent Events , New Drug Application , European Network , Prescription Drug User Fee Act , European Association , Akcea Merger , North America , Akcea Therapeutics , Consolidated Statements , Except Per Share Data , Consolidated Operating Expenses ,

Ionis reports first quarter financial results and recent business achievements

/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements. "We. ....

United States , Elizabethl Hougen , Muscular Dystrophy Association , American College Of Cardiology , Ionis Pharmaceuticals Inc , American Academy Of Allergy , Development Expenses , Development Revenue , American Academy Of Neurology , Ionis Pharmaceuticals , Akcea Therapeutics Inc , Technology Advancements , Financial Results , American Academy , Latin America , Swedish Orphan Biovitrum , Recent Events , European Heart Journal , New England Journal , American College , Akcea Merger , North America , Akcea Therapeutics , Consolidated Statements , Except Per Share Data , Consolidated Operating Expenses ,